Erratum to Prevalence of Nonalcoholic Steatohepatitis Among Patients with Resectable Intrahepatic Cholangiocarcinoma (J Gastrointest Surg., (2013), 17, (748-755), 10.1007/s11605-013-2149-x);Prevalence of Nonalcoholic Steatohepatitis Among Patients with Resectable Intrahepatic Cholangiocarcinoma

Journal of Gastrointestinal Surgery

Volumn 17, Issue 4, 2013, Pages 748-755

  Reddy, Srinevas K ^a   Hyder, Omar ^b   Marsh, J Wallis ^c   Sotiropoulos, Georgios C ^d   Paul, Andreas ^d   Alexandrescu, Sorin ^e   Marques, Hugo ^f   Pulitano, Carlo ^g   Barroso, Eduardo ^f   Aldrighetti, Luca ^g   Geller, David A ^c   Sempoux, Christine ^h   Herlea, Vlad ^e   Popescu, Irinel ^e   Anders, Robert ^b   Rubbia Brandt, Laura ⁱ   Gigot, Jean Francois ⁱ   Mentha, Giles ⁱ   Pawlik, Timothy M ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e FUNDENI CLINICAL INSTITUTE   (Romania)

^f HOSPITAL CURRY CABRAL   (Portugal)

^g SAN RAFFAELE HOSPITAL   (Italy)

^h CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

ⁱ GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Intrahepatic cholangiocarcinoma; Nonalcoholic fatty liver disease; Nonalcoholic fatty liver disease activity score; Nonalcoholic steatohepatitis

Indexed keywords

EID: 84875025976     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-013-2323-1     Document Type: Erratum

References (41)

1. Hashimoto E, Tokushige K. Prevalence, gender, ethnic variations, and prognosis of NASH. J Gastroenterol 2011; 46(Suppl): 63-9.
2. Pascale A, Pais R, Ratziu V. An overview of nonalcoholic steatohepatitis: past, present, and future directions. J Gastrointest Liver Dis 2010; 19: 415-23.
3. Younossi AM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1998 to 2008. Clin Gastroenterol Hepatol 2011; 9: 524-30.
4. Michitaka K Nishiguchi S, Aoyagi Y, Hiasa Y, Tokumoto Y, Onji M; Japan Etiology of Liver Cirrhosis Study Group. Etiology of liver cirrhosis in Japan: a nationwide survey. J Gastoenterol 2010; 45: 86-94.
5. Bhala N, Angulo P, van der Poorten D, Lee E, Hui JM, Saracco G, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011; 54: 1208-16.
6. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51: 1820-32.
7. Page JM, Harrison SA. NASH and HCC. Clin Liver Dis 2009; 13: 631-47.
8. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 2011; 332: 1519-23.
9. Aly EZ, Kleiner DE. Update on fatty liver disease and steatohepatitis. Adv Anat Pathol 2011; 18: 294-300.
10. Argo CK, Northup PG, Al-Osaimi AMS, Caldwell SH. Systemic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009; 51: 371-9.
11. Reddy SK, Steel JL, Chen HW, DeMateo DJ, Cardinal J, Behari J, et al. Outcomes of curative treatment for hepatocellular caner in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology 2012; 55: 1809-19.
12. SEER Cancer Statistics Review, 1975-2000. SEER incidence and US mortality rates and trends for the top 15 cancer sites by race/ethnicity. http://seer. cancer. gov/csr/1975_2009_pops09/results_merged/topic_topfifteen.pdf.
13. SEER Cancer Statistics Review, 1975-2000. CSR sections-liver and bile duct. http://seer. cancer. gov/csr/1975_2009_pops2009/results_merged/sect_14_liver_bile. pdf.
14. Hashimoto E, Yatsuji S, Tobari M, Taniai M, Torii N, Tokushige K, Shiratori K. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol 2009; 44(Suppl XIX): 89-95.
15. Stickel F, Hellerbrand C. Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. Gut 2010; 29: 1303-7.
16. Ascha M, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972-8.
17. Tokushige K, Hasimoto E, Yatsuji S, Tobari M, Taniai M, Torii N, Shiratori K. Prospective study of hepatocellular carcinoma in nonalcoholic steatohepatitis in comparison with hepatocellular carcinoma caused by chronic hepatitis C. J Gastroenterol 2010; 45: 960-7.
18. Kawada N, Imanaka K, Kawaguchi T, Tamai C, Ishihara R, Matsunaga T, et al. Hepatocellular carcinoma arising from non-cirrhotic alcoholic steatohepatitis. J Gastroenterol 2009; 44: 1190-4.
19. Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-Tainturier MH, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002; 35: 1485-93.
20. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-40.
21. Yasui K, Hashimoto E, Komorizono Y, Koike K, Arii S, Imai Y, et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011; 9: 428-33.
22. Yoshioka Y, Hashimoto E, Yatsuji S, Kaneda H, Taniai M, Tokushige K, Shiratori K. Nonalcoholic steatohepatitis: cirrhosis, hepatocellular carcinoma, and burnt-out NASH. J Gastroenterol 2004; 39: 1215-8.
23. Welzel TM, Mellemkjaer L, Gloria G, Sakoda LC, Hsing AW, El Ghormli L, et al. Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: A nationwide case-control study. Int J Cancer 2006; 120: 638-41.
24. de Jong MC, Nathan H, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol 2011; 29: 3140-5.
25. Eckel RH, Alberti KGMM, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2010; 375: 181-3.
26. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-5.
27. Ascha MS, Hanounch IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972-8.
28. Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalsani N, Lavine JE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatits. Hepatology 2011; 54: 344-53.
29. Strasberg SM. Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system. J Hepatobiliary and Pancreat Surg 2005; 12: 351-5.
30. th ed. New York: Springer; 2002.
31. Kleiner DE, Brunt EM, van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
32. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA, NASH Clinical Research Network (CRN). Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011; 53: 810-20.
33. Brunt EM, Kleiner DE, Wilson LA, Unalp A, Behling CE, Lavine JE, et al. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology 2009; 49: 809-20.
34. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-23.
35. Kleiner DE, Brunt EM. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis 2012; 32: 3-13.
36. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
37. Welzel TM, Graubard BI, El-Serag HB, Shaib YH, Hsing AW, Davila JA, McGlynn KA. Risk factors for intra- and extrahepatic cholangiocarcinoma in the United States: a population based case-control study. Clin Gastroenterol Hepatol 2007; 5: 1221-8.
38. Lefkowitch JH, Morawski JL. Late nonalcoholic fatty liver disease with cirrhosis: a pathologic case of lost or mistaken identity. Semin Liver Dis 2012; 32: 92-8.
39. Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare Database. Hepatology 2011; 54: 463-71.
40. Reddy SK, Marsh JW, Varley PR, Mock BK, Chopra KB, et al (2012) Underlying steatohepatitis, but not simple hepatic steatosis, increases morbidity after liver resection: a case-control study. Hepatology. doi: 10/1002/hep. 25935.
41. Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, Vilgrain V, et al. Hepatocellular carcinoma in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009; 49: 851-9.